Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505187 · ClinicalTrials.gov registry record · Phase 2
Celecoxib for ENT Pain Management
A Phase 2 study of Parotidectomy, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT06505187: Recruiting Phase 2 study of Parotidectomy, sponsored by University of Wisconsin, Madison.
NCT06505187 is a Phase 2 study of Parotidectomy that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06505187, a Phase 2 study of Parotidectomy, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tylenol to a placebo to find out whether celecoxib works to manage pain. Participants will: * Take celecoxib, or a placebo, plus Tylenol with opioids as needed * Keep a diary of their pain between visits * Complete questionnaires
Primary Outcome
Total number of oxycodone pills taken during the first 7 days post-operative
Conditions Studied
Interventions
- DRUG placebo
- DRUG Celecoxib
- DRUG Tylenol
- DRUG Oxycodone
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06505187 shows while recruiting
NCT06505187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Parotidectomy appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT06505187 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06505187 about?
NCT06505187 is a clinical study titled "Celecoxib for ENT Pain Management". The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tyleno...
What is the current status of trial NCT06505187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2025-02-28. Estimated completion is 2026-09.
What conditions does trial NCT06505187 study?
This clinical trial studies the following conditions: Parotidectomy.
What interventions are being tested in trial NCT06505187?
The interventions under investigation include: placebo (DRUG), Celecoxib (DRUG), Tylenol (DRUG), Oxycodone (DRUG).
Who is sponsoring clinical trial NCT06505187?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505187 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06505187's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,174 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI